Detecting T790M mutation of tissue and plasma ctDNA samples by ARMS in EGFR-mutant NSCLC patients after disease progression

被引：2
|
作者：
Wu, Ya-Lan
Tong, Rui-Zhan
Zhang, Yan
Hu, Bin -Bin
Zhen, Ke
Zhao, Qian
Zhou, Xiao-Juan
Ding, Zhen-Yu
Peng, Feng
Gong, You-Ling
Xu, Yong
Wang, Jin
Ren, Li
Liu, Yong-Mei
Lu, You
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.e20625
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e20625
引用
收藏
页数：5
相关论文
共 50 条
  • [1] Osimertinib Benefit in ctDNA T790M Positive, EGFR-Mutant NSCLC Patients
    Remon, Jordi
    Caramella, Caroline
    Joelet, Cecile
    Lacroix, Ludovic
    Lawson, Andrew
    Smalley, Sarah
    Howarth, Karen
    Gale, Davina
    Rosenfeld, Nitzan
    Green, Emma
    Plagnol, Vincent
    Planchard, David
    Bluthgen, Maria
    Gazzah, Annas
    Pannet, Chloe
    Nicotra, Claudio
    Soria, Jean-Charles
    Besse, Benjamin
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1254 - S1255
  • [2] Predictive factors and prognostic significance of T790M mutation in patients with EGFR-mutant NSCLC
    Hwang, Ji An
    Choi, Chang-Min
    Lee, Jae Cheol
    EUROPEAN RESPIRATORY JOURNAL, 2017, 50
  • [3] Exploratory study on detecting EGFR mutation including T790M with blood samples from patients with NSCLC
    Kawamura, Takahisa
    Murakami, Haruyasu
    Kenmotsu, Hirotsugu
    CANCER SCIENCE, 2018, 109 : 1100 - 1100
  • [4] Monitoring of T790M in plasma ctDNA of advanced EGFR-mutant NSCLC patients on first- or second-generation tyrosine kinase inhibitors
    Chun-Ta Huang
    Chih-An Lin
    Te-Jen Su
    Ching-Yao Yang
    Tzu-Hsiu Tsai
    Chia-Lin Hsu
    Wei-Yu Liao
    Kuan-Yu Chen
    Chao-Chi Ho
    Chong-Jen Yu
    BMC Cancer, 23
  • [5] Monitoring of T790M in plasma ctDNA of advanced EGFR-mutant NSCLC patients on first- or second-generation tyrosine kinase inhibitors
    Huang, Chun-Ta
    Lin, Chih-An
    Su, Te-Jen
    Yang, Ching-Yao
    Tsai, Tzu-Hsiu
    Hsu, Chia-Lin
    Liao, Wei-Yu
    Chen, Kuan-Yu
    Ho, Chao-Chi
    Yu, Chong-Jen
    BMC CANCER, 2023, 23 (01)
  • [6] Tracking spatiotemporal T790M heterogeneity in patients with EGFR-mutant advanced NSCLC after acquired resistance to EGFR TKIs
    Zhang, Y-C.
    Pi, C.
    Ke, E-E.
    Chen, Z-H.
    Su, J.
    Dong, Z-Y.
    Xu, C-R.
    Yan, H-H.
    Tu, H-Y.
    Zhong, W-Z.
    Zhang, X-C.
    Yang, J-J.
    Yang, X-N.
    Zhou, Q.
    Wu, Y-L.
    ANNALS OF ONCOLOGY, 2016, 27
  • [7] Tracing Spatiotemporal T790M Heterogeneity in Patients with EGFR-Mutant Advanced NSCLC after Acquired Resistance to EGFR TKIs
    Zhang, Yi-Chen
    Pi, Can
    Ke, E-E
    Chen, Zhi-Hong
    Su, Jian
    Dong, Zhong-Yi
    Xu, Chong-Rui
    Tu, Hai-Yan
    Yan, Hong-Hong
    Zhong, Wen-Zhao
    Yang, Jin-Ji
    Zhang, Xu-Chao
    Wu, Yi Long
    Zhou, Qing
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1249 - S1249
  • [8] A Comparison of ddPCR and ARMS for detecting EGFR T790M status in ctDNA from advanced NSCLC patients with acquired EGFR-TKI resistance
    Wang, Wenxian
    Song, Zhengbo
    Zhang, Yiping
    CANCER MEDICINE, 2017, 6 (01): : 154 - 162
  • [9] Loss of T790M Mutation is Associated with Early Progression to Osimertinib in Chinese Advanced NSCLC Patients Harboring EGFR T790M
    Zhao, S.
    Jiang, T.
    Li, X.
    Zhao, C.
    Su, C.
    Ren, S.
    Zhou, C.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S410 - S410
  • [10] Frequency and abundance of plasma T790M mutation associated with failure patterns of EGFR-mutant NSCLC treated with tyrosine kinase inhibitors
    Zhang, S.
    Zhu, L.
    Xia, B.
    Chen, E.
    Zhao, Q.
    Chen, X.
    Wang, L.
    Jiang, H.
    Ma, S.
    ANNALS OF ONCOLOGY, 2016, 27
12345